Data / Form D filings / BELLICUM PHARMACEUTICALS, INC
BELLICUM PHARMACEUTICALS, INC: Form D filings
BELLICUM PHARMACEUTICALS, INC, a pharmaceuticals company in Houston, TX, filed 6 Form D notices with the SEC between 2009 and 2014. The latest, on September 3, 2014, reports $94.4 million sold of a $94.4 million offering to 76 investors.
Find out what BELLICUM PHARMACEUTICALS, INC does, who founded it and who invested, beyond what the filing says. $10 of credit on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 2130 West Holcombe Boulevard, Suite 850, Houston, TX, 77030
- Phone
- (832) 384-1100
- Industry
- Pharmaceuticals
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1358403
The full lists. Form D filings in Texas: 4,800 rows, $128, or the new rows each week for $19 a month. Form D filings in Pharmaceuticals: 346 rows, $17.30, or the new rows each week for $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (company, CIK, year incorporated, street, city, state and 5 more), which open on your screen as soon as the payment clears and come by email. For agents and scripts: every list with its row count and price is at https://specstream.ai/data/lists.json.
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Sep 3, 2014 | New notice | $94,357,588 | $94,357,588 | $0 | 76 | Aug 22, 2014 | sec.gov |
| Oct 16, 2013 | Amendment | $35,000,000 | $19,649,134 | $15,350,866 | 21 | Nov 9, 2011 | sec.gov |
| Mar 22, 2012 | New notice | $25,000,002 | $19,889,803 | $5,110,199 | 21 | Nov 9, 2011 | sec.gov |
| Oct 25, 2010 | New notice | $3,000,000 | $1,175,000 | $1,825,000 | 10 | Sep 30, 2010 | sec.gov |
| Oct 21, 2009 | New notice | $2,500,000 | $1,250,000 | $1,250,000 | 17 | Oct 16, 2009 | sec.gov |
| Mar 31, 2009 | New notice | $1,500,000 | $500,000 | $1,000,000 | 11 | Mar 25, 2009 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| David M. Spencer | Executive Officer | |
| Annemarie K. Moseley | Executive Officer | |
| Kevin M. Slawin | Director | |
| Dennis K. Stone | Director | |
| James F. Brown | Director | |
| Frank M. McGuyer | Director | |
| Ken K. Moseley | Executive Officer | |
| Thomas J. Farrell | Executive Officer, Director |
Other pharmaceuticals companies in Texas that filed recently
- LUCIER PHARMACEUTICALS INC offering · Oct 13, 2026
- FibroBiologics, Inc. $1.2 million · Oct 13, 2026
- Eos SENOLYTIX, Inc. $750,000 · Aug 27, 2026
Every Form D from the week of Sep 1, 2014 · All recent filings in Texas · All recent Pharmaceuticals filings
Read from SEC EDGAR. Amount sold is what BELLICUM PHARMACEUTICALS, INC reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.
$10 of credit on sign-up, no card.